News | May 21, 2015

Amaranth Medical Reports Data for Two FORTITUDE Bioresorbable Scaffold Studies at EuroPCR 2015

Device has, to date, navigated complex anatomies with no peri-procedural complications

Amaranth Medical, Fortitude BRS, MEND-II, RENASCENT, EuroPCR 2015

Image courtesy of Amaranth Medical

May 18, 2015 — Amaranth Medical announced plans to report clinical results from the company's ongoing trial of its second-generation Fortitude sirolimus-eluting bioresorbable scaffold (BRS) at EuroPCR 2015. Juan F. Granada, M.D., executive director and chief innovation officer of the CRF-Skirball Center for Innovation (SCI), will present these updates.

The Fortitude sirolimus-eluting BRS is being evaluated in two multi-center, international trials, both of which are designed to support a planned application for CE Mark. In this clinical program, a total 49 patients have been treated in centers in Colombia, South America (MEND-II trial) and Italy (RENASCENT trial). Early preliminary results from these studies demonstrate the scaffold's capabilities to navigate through complex anatomies with a balance of deliverability and biomechanical performance. No peri-procedural complications have been reported to date.

"Our clinical trial experience with the Fortitude BRS is very encouraging," commented Granada, primary investigator of the MEND-II study. "Building upon its high biocompatibility profile, the Fortitude BRS exhibits the biomechanical behavior expected by the interventional community in addition to the long-term vascular benefits of device absorption, both of which have significant impact on clinical outcomes. Specifically, the Fortitude BRS has the capability to over-expand approximately four-fold what is possible with commercially available BRS, providing physicians with the operational flexibility we have with metallic scaffolds."

Antonio Colombo, M.D., director of the cardiac cath lab and interventional cardiology unit, EMO-GVM Centro Cuore Columbus in Milan, Italy, and primary investigator of the RENASCENT trial, added, "While results from the RENASCENT study are still early, we are encouraged by the acute performance of the device, which shows no indication of device failure or peri-procedural complications, further supporting the mechanical strength and durability of the device platform. I look forward to enrolling additional patients and completing nine?month imaging follow-up visits, which will unveil the real potential of this second-generation BRS platform."

Additional details of Amaranth's technology clinical program will be provided by Granada in a presentation titled: "Bench Testing and Pre-Clinical Evaluation of the Amaranth PLLA Scaffold."

The MEND-II and RENASCENT trials are built upon the successful results from MEND-I, the first-in-human clinical study of Amaranth's bare Fortitude BRS, which was conducted in Colombia, South America. This study met its primary endpoint at six months. Patients who had been enrolled in MEND-I continue to show excellent clinical performance two years after implant. Further, angiographic and optical coherence tomography (OCT) follow-up demonstrate late lumen gain in treated vessels at two years, relative to six months.

For more information: www.amaranthmedical.com

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init